Delivery Order SPE2DR25D9113-SPE2DR26FCJC8
Award Date 4/30/26
Potential Completion Date 5/1/26
Potential Value $13K
Federal Agency
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency issued a $25,165.90 delivery order to DMS Pharmaceutical Group Inc. on April 29, 2026, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for JAKAFI 15 MG tablets (60-count units). PPV-G GEN V is a single-award indefinite delivery contract through which the Defense Logistics Agency authorizes firm fixed-price delivery orders for pharmaceutical products and medical consumables supporting Department of Defense military healthcare facilities...
- The Defense Logistics Agency issued a $12,663.27 delivery order to DMS Pharmaceutical Group Inc. on April 22, 2026, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for JAKAFI 10 mg tablets (60-count units), with an ultimate completion date of April 23, 2026. PPV-G GEN V is a Defense Logistics Agency single-award indefinite delivery contract with a $499.999 billion ceiling through December 31, 2036, structured with a 30-month base period and three 30-month option...
- The Defense Logistics Agency issued a $25,326.56 delivery order to DMS Pharmaceutical Group Inc. on April 27, 2026, for JAKAFI 10 mg tablets (60-count units) under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). PPV-G GEN V is a Defense Logistics Agency single-award indefinite delivery contract with a $499.999 billion ceiling authorizing firm fixed-price delivery orders for pharmaceutical products and medical consumables supporting Department of Defense military...
- The Defense Logistics Agency issued a $16,526.95 delivery order to DMS Pharmaceutical Group Inc. on March 10, 2026, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for JAKAFI 10 mg tablets (60-count). PPV-G GEN V is the Defense Logistics Agency's single-award indefinite delivery contract for pharmaceutical products and medical consumables supporting Department of Defense healthcare operations worldwide. DMS Pharmaceutical Group Inc. is a woman-owned small business...
- The Defense Logistics Agency issued a $37,989.81 delivery order to DMS Pharmaceutical Group Inc. on April 27, 2026, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for supply of JAKAFI 10 mg tablets (60-count units). PPV-G GEN V is the Defense Logistics Agency's single-award indefinite delivery contract for branded and generic prescription drugs, biologics, over-the-counter medications, vaccines, and medical consumables to Department of Defense military healthcare...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on March 6, 2026, for $50,653.12 (ceiling value) under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for supply of JAKAFI 10 mg tablets (60-count). PPV-G GEN V is a Defense Logistics Agency single-award Indefinite Delivery Contract authorizing firm fixed-price delivery orders for pharmaceutical products, biologics, and medical consumables to support Department of Defense military...
- The Defense Logistics Agency issued a $12,663.27 delivery order to DMS Pharmaceutical Group Inc. on March 4, 2026, for JAKAFI 10 mg tablets (60-count units) under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). PPV-G GEN V is a Defense Logistics Agency indefinite delivery contract supporting pharmaceutical supply to Department of Defense military healthcare facilities worldwide. DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler....
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on April 3, 2026, for JAKAFI 10 mg tablets (60 count) with a ceiling value of $12,663.27 under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). PPV-G GEN V is a Defense Logistics Agency single-award indefinite delivery contract authorizing firm fixed-price delivery orders for pharmaceutical products, biologics, and medical consumables supporting Department of Defense military...
- The Defense Logistics Agency issued a $12,663.27 delivery order to DMS Pharmaceutical Group Inc. on March 3, 2026, for JAKAFI 10 mg tablets (60 count) under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). PPV-G GEN V is the Defense Logistics Agency's indefinite delivery contract authorizing firm fixed-price delivery orders for branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support Department of Defense...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on April 17, 2026, for JAKAFI 10 mg tablets (60-count), with a ceiling value of $75,979.68 under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). PPV-G GEN V is the Defense Logistics Agency's single-award indefinite delivery contract for pharmaceutical and medical consumable supply to Department of Defense military healthcare facilities worldwide. DMS Pharmaceutical is the sole...
- SPE2DR25D9113Indefinite Delivery Contract
- SPE2DR25D9113-SPE2DR26FCJC8Delivery Order
The Defense Logistics Agency issued a $12,663.27 delivery order to DMS Pharmaceutical Group Inc. on April 30, 2026, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for JAKAFI 10 mg tablets. PPV-G GEN V is the Defense Logistics Agency's single-award indefinite delivery contract for pharmaceutical products and medical consumables supporting Department of Defense military healthcare facilities worldwide. The parent contract SPE2DX carries a $499.999 billion ceiling and runs through December 31, 2036. Place of performance is Park Ridge, Illinois. The delivery order ultimate completion date is May 1, 2026. DMS Pharmaceutical Group Inc. is a woman-owned small business.
Generated 7/29/26, 9:46 AM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.7k | 4/29/26 |